Executive function asymmetry in older adults genetically at-risk for Alzheimer's disease: Verbal versus design fluency

Recent studies have reported cognitive asymmetries in patients with Alzheimer's disease (AD) and in individuals with apolipoprotein E ε4 (APOE ε4) genotype who are in the preclinical phase of AD. This increased frequency of cognitive asymmetry, typically defined as a significant discrepancy (in either direction) between verbal and spatial abilities, often occurs despite an absence of differences on traditional measures of central tendency (i.e., mean test scores). We prospectively studied the relationship between APOE genotype and two modality-specific executive-function tasks: The Verbal Fluency and Design Fluency tests of the Delis-Kaplan Executive Function System (D-KEFS) in 52 normal functioning older adult participants who were grouped according to the presence (n = 24) or absence (n = 28) of the APOE ε4 allele. Nondemented older adults with the APOE ε4 allele demonstrated a greater frequency of cognitive asymmetric profile on the new switching conditions of the Verbal and Design Fluency measures than the APOE non-ε4 individuals. This study further supports the utility of assessing cognitive asymmetry for the detection of subtle cognitive differences in individuals at-risk for AD, and suggests that dual-task executive function tests (i.e., fluency plus switching) may serve as a useful preclinical marker of AD. (JINS, 2005, 11, 863–870.)

[1]  Allen D. Roses,et al.  A model for susceptibility polymorphisms for complex diseases: apolipoprotein E and Alzheimer disease , 1997, Neurogenetics.

[2]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[3]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[4]  L. Bieliauskas,et al.  Neuropsychological subgroups of patients with Alzheimer's disease: an examination of the first 10 years of CERAD data. , 1999, Journal of clinical and experimental neuropsychology.

[5]  W. F. Vonderhaar.  A COMPARATIVE STUDY OF PERFORMANCE SCALE IQ'S AND SUBTEST SCORES OF DEAF CHILDREN ON THE WECHSLER INTELLIGENCE SCALE FOR CHILDREN AND THE WECHSLER INTELLIGENCE SCALE FOR CHILDREN-REVISED , 1977 .

[6]  Mayo Clinic,et al.  PRECLINICAL EVIDENCE OF ALZHEIMER’S DISEASE IN PERSONS HOMOZYGOUS FOR THE , 2000 .

[7]  L. Thal,et al.  Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double cross-validation and application to a community-dwelling sample. , 1995, Archives of neurology.

[8]  Mark S. Cohen,et al.  Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.

[9]  M. Albert,et al.  Apolipoprotein E epsilon4 and incidence of Alzheimer disease in a community population of older persons. , 1997, JAMA.

[10]  E. Corder,et al.  Attenuation of apolipoprotein E ∈4 allele gene dose in late age , 1996, The Lancet.

[11]  Jong-Won Kim,et al.  Effects of apolipoprotein E phenotypes on the neuropsychological functions of community-dwelling elderly individuals without dementia , 2000, Neuroscience Letters.

[12]  E. Giacobini.  Cholinesterase Inhibitors Stabilize Alzheimer Disease , 2000, Neurochemical Research.

[13]  Ronald C Petersen,et al.  Cognitive asymmetries associated with apolipoprotein E genotype in patients with Alzheimer's disease , 2003, Journal of the International Neuropsychological Society.

[14]  Yaakov Stern,et al.  Memory performance in healthy elderly without Alzheimer’s disease: effects of time and apolipoprotein-E , 2001, Neurobiology of Aging.

[15]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[16]  L. Bäckman,et al.  Three-year changes in cognitive performance as a function of apolipoprotein E genotype: evidence from very old adults without dementia. , 1998, Psychology and aging.

[17]  D. Delis,et al.  Spatial cognition in Alzheimer's disease: subtypes of global-local impairment. , 1992, Journal of clinical and experimental neuropsychology.

[18]  D. Delis,et al.  Do neuropsychological tests detect preclinical Alzheimer's disease: individual-test versus cognitive-discrepancy score analyses. , 2002, Neuropsychology.

[19]  O. Paulson,et al.  Single Photon Emission Computed Tomography and Apolipoprotein E in Alzheimer's Disease: Impact of the ε4 Allele on Regional Cerebral Blood Flow , 2001 .

[20]  A. Mackinnon,et al.  Apolipoprotein E allele ∈4, dementia, and cognitive decline in a population sample , 1995, The Lancet.

[21]  J. Haxby,et al.  Relations between Neuropsychological and Cerebral Metabolic Asymmetries in Early Alzheimer's Disease , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  Douglas Galasko,et al.  Decline in verbal memory during preclinical Alzheimer's disease: Examination of the effect of APOE genotype , 2002, Journal of the International Neuropsychological Society.

[23]  E. Kaplan,et al.  The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. , 1995, Archives of neurology.

[24]  M. Albert,et al.  Preclinical prediction of AD using neuropsychological tests , 2001, Journal of the International Neuropsychological Society.

[25]  Myrna F. Schwartz,et al.  Modular deficits in Alzheimer-type dementia , 1990 .

[26]  K. Marder,et al.  Neuropsychological detection and characterization of preclinical Alzheimer's disease , 1995, Neurology.

[27]  D. Delis,et al.  Do Subgroups of Patients With Alzheimers Disease Exhibit Asymmetric Deficits on Memory Tests? , 2001, Journal of clinical and experimental neuropsychology.

[28]  Jewel Swanson.  The Delis-Kaplan Executive Function System , 2005 .

[29]  G. Alexander,et al.  Declining brain activity in cognitively normal apolipoprotein E ɛ4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  N Butters,et al.  Episodic memory changes are associated with the APOE- epsilon 4 allele in nondemented older adults , 1995, Neurology.

[31]  Richard J. Caselli,et al.  Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study , 2001, Journal of the Neurological Sciences.

[32]  L. Thal,et al.  Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. , 1999, Psychology and aging.

[33]  Steven D. Edland,et al.  Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease , 1998, Neurology.

[34]  E G Tangalos,et al.  Apolipoprotein E genotype influences cognitive ‘phenotype’ in patients with Alzheimer's disease but not in healthy control subjects , 1998, Neurology.

[35]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[36]  L. Thal,et al.  Neurological findings in Alzheimer's disease and normal aging. , 1990, Archives of neurology.

[37]  M. Yamada,et al.  [Dementia rating scale]. , 1997, Nihon rinsho. Japanese journal of clinical medicine.

[38]  J C Mazziotta,et al.  Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. , 1995, JAMA.

[39]  Janice E. Knoefel,et al.  Apolipoprotein E element 4 association with dementia in a population-based study , 1996, Neurology.

[40]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[41]  C. Kessler,et al.  Apolipoprotein E4 Promotes Incipient Alzheimer Pathology in the Elderly , 1998, Alzheimer disease and associated disorders.

[42]  Roberta F. White,et al.  The preclinical phase of alzheimer disease: A 22-year prospective study of the Framingham Cohort. , 2000, Archives of neurology.